» Articles » PMID: 12531514

Up-regulation of Mitogen-activated Protein Kinases ERK1/2 and MEK1/2 is Associated with the Progression of Neurofibrillary Degeneration in Alzheimer's Disease

Overview
Date 2003 Jan 18
PMID 12531514
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

The abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) has been proposed to involve the extracellular-signal-regulated protein kinase (ERK) of the mitogen-activated protein (MAP) kinase family. ERK is phosphorylated and thereby activated by MAP kinase kinase (MEK). In the present study, we determined the intracellular and regional distribution of the active forms of both MEK1/2 and ERK1/2, i.e. p-MEK1/2 and p-ERK1/2 in the entorhinal, hippocampal, and temporal cortices of 49 brains staged for neurofibrillary changes according to Braak and Braak's protocol. We found that p-MEK1/2 and p-ERK1/2 were present in the initial stages of neurofibrillary degeneration in the projecting neurons in the transentorhinal region, and extended into other brain regions co-incident with the progressive sequence of neurofibrillary changes up to and including Braak stage VI. It appeared that the accumulation of p-MEK1/2 and p-ERK1/2 was initiated in the cytoplasm of pretangle neurons in varying size granules, which grew into large aggregates co-existing with the progressive development of neurofibrillary tangles. Accumulation of p-MEK1/2 and p-ERK1/2 was found in cases with stages I-III neurofibrillary degeneration, which were devoid of amyloid deposition. These data provide direct in situ evidence consistent with the possible involvement of MAP kinase pathway in the hyperphosphorylation of tau and the presence of this lesion before deposition of beta-amyloid in AD.

Citing Articles

Neuroproteomic Analysis after SARS-CoV-2 Infection Reveals Overrepresented Neurodegeneration Pathways and Disrupted Metabolic Pathways.

Basak I, Harfoot R, Palmer J, Kumar A, Quinones-Mateu M, Schweitzer L Biomolecules. 2023; 13(11).

PMID: 38002279 PMC: 10669333. DOI: 10.3390/biom13111597.


Nuclear ERK1/2 signaling potentiation enhances neuroprotection and cognition via Importinα1/KPNA2.

Indrigo M, Morella I, Orellana D, dIsa R, Papale A, Parra R EMBO Mol Med. 2023; 15(11):e15984.

PMID: 37792911 PMC: 10630888. DOI: 10.15252/emmm.202215984.


Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer's disease.

Kim M, Kim M, Lee C, Lee J, Kim S, Hong S Exp Mol Med. 2023; 55(10):2177-2189.

PMID: 37779138 PMC: 10618442. DOI: 10.1038/s12276-023-01073-2.


Analysis of Why Alzheimer's Dementia Never Spontaneously Reverses, Suggests the Basis for Curative Treatment.

Fessel J J Clin Med. 2023; 12(14).

PMID: 37510988 PMC: 10381682. DOI: 10.3390/jcm12144873.


Vascular endothelial growth factor isoforms differentially protect neurons against neurotoxic events associated with Alzheimer's disease.

Alalwany R, Hawtrey T, Morgan K, Morris J, Donaldson L, Bates D Front Mol Neurosci. 2023; 16:1181626.

PMID: 37456522 PMC: 10349181. DOI: 10.3389/fnmol.2023.1181626.